Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the … See more History of Patent laws and pharma industry in India As part of the Commonwealth, India inherited its intellectual property laws from Great Britain. However, after gaining independence in … See more Novartis The legal team of Novartis was led by ex-Solicitor General of India Gopal Subramaniam and senior advocate T. R. Andhyarujina. … See more The decision received extensive coverage from Indian and international media. It reignited debates on balancing public good with monopolistic pricing and innovation with affordability. Several commenters, including Novartis, noted that a … See more Supreme Court decided the matter de novo looking into matters of both fact and law. The court first analysed the question of prior art by looking into Zimmerman patent and the related … See more WebSep 14, 2013 · CASE ANALYSIS Assignment No. 3 Patent Law1 Name of the Case : - Novartis A.G. v/s Union of India Citation :- (2007) 4 MLJ 1153 Date of Judgement : - 6 August, 2007 Names of the Judge/s : -R. Balasubramanian, J. and PrabhaSridevan J. Provisions Involved :- Article 14 of the Constitution of India Article 27 and Article 64of the …
Novartis v. Union of India & Others - Wikiwand
WebSupreme Court of India. Novartis Ag vs Union Of India & Ors on 1 April, 2013. Author: ..…..………………………..J. Bench: Aftab Alam, Ranjana Prakash Desai. REPORTABLE IN THE SUPREME COURT OF INDIA CIVIL APPELLATE JURISDICTION CIVIL APPEAL Nos. 2706-2716 OF 2013 (ARISING OUT OF SLP(C) Nos. 20539-20549 OF 2009)NOVARTIS AG … WebAug 21, 2024 · Novartis AG v. Union of India & Others CITATION: (2013) 6 SCC 1 COURT: Supreme Court of India. BENCH: Aftab Alam, J.; Ranjana Prakash Desai, J. FACTS One of the predominant pharmaceutical companies, Novartis International (The Appellant) filed an application for patent registration of a drug called ‘Glivec’. cysteine pantothenic acid
Novartis AG v. Union of India & Others (Supreme Court of India, 1 …
WebSep 19, 2013 · The Indian Supreme Court’s decision in Novartis v Union of India (UOI), decided earlier this year, formalizes a concerted and focused attempt by Indian law-makers to reject trivial secondary pharmaceutical inventions. WebJun 25, 2024 · The case of Novartis AG v. Union of India (Civil Appeal Nos. 2706-2716 of 2013) , is the most distinguished judgment on the Patent rights in India. Novartis was not allowed to patent the drug ‘Imatnib Mesylate’ marketed under the name “Gleevec”, for lack of invention, novelty and non-obviousness. WebJan 1, 2024 · Novartis AG v. Union of India and Others - Volume 175. Held:— The appellant’s petition was dismissed. (1) In order to interpret the relevant provisions of the Patent Act, it was important to understand the legislative intention and the reason behind the changes in the definition of invention in Section 2(1)(j), the insertion of new terms in the form of … cysteine is what type of amino acid